TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03512808
Drug: Urso Forte 500Mg Tablet
Normalized name: Urso Forte 500mg Tablet
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urso forte 500mg tablets followed by Ursodiol 500mg tablets
Study: NCT03189615
Drug: Lu AF35700
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 10 mg Lu AF35700
Study: NCT00661726
Drug: Decitabine (USAN, INN)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
Study: NCT03533959
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: the administration of Alirocumab at least 75mg every 2 weeks
Study: NCT00426582
Drug: Patupilone
Normalized name: Patupilone
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00086528
Drug: XL647
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
Study: NCT00540241
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: in-label use
Study: NCT02147197
Drug: Ulipristal acetate (UPA)
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: UPA tablet
Study: NCT01321255
Drug: FDC
Normalized name: FDCYD
DrugBank: 5-fluoro-2'-deoxycytidine (DB12957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
Study: NCT01198210
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local peritonsillar infiltration of 2 ml saline,
Study: NCT01198210
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local peritonsillar infiltration of ketamine (0.5 mg/kg)
Study: NCT01198210
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: local peritonsillar infiltration dexamethasone (0.2 mg/kg))
Study: NCT01198210
Drug: ketamine-dexamethasone
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
Study: NCT00830375
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-30mg, by mouth, daily
Study: NCT02326168
Drug: Bacillus Calmette-Guerin (BCG)
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation for non-muscle invasive bladder cancer
Study: NCT00255918
Drug: Dimethoxybenzylidene anabaseine (DMXB-A)
Normalized name: Dimethoxybenzylidene anabaseine
DrugBank: GTS-21 (DB05708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
Study: NCT00255918
Drug: Dimethoxybenzylidene anabaseine (DMXB-A)
Normalized name: Dimethoxybenzylidene anabaseine
DrugBank: GTS-21 (DB05708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
Study: NCT04357730
Drug: Alteplase 50 MG [Activase]
Normalized name: alteplase 50 MG [Activase]
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
Study: NCT04357730
Drug: Alteplase 50 MG [Activase]
Normalized name: alteplase 50 MG [Activase]
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
Study: NCT01335893
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
Study: NCT03419897
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT01012492
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
Study: NCT02897037
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
Study: NCT01527305
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
Study: NCT02482428
Drug: Aldara
Normalized name: Aldara
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Applied 3 times a week for 16 weeks
Study: NCT00945347
Drug: Miglustat
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nasal instillation of miglustat
Study: NCT02407080
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
Study: NCT02744495
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
Study: NCT02744495
Drug: Droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
Study: NCT03347526
Drug: Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injectable + oral solution
Study: NCT03347526
Drug: Vigabatrin
Normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01097265
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01934712
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose injected subcutaneously (s.c, under the skin)
Study: NCT01934712
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose injected subcutaneously (s.c, under the skin)
Study: NCT00443872
Drug: orally disintegrating selegiline (Zelapar)
Normalized name: selegiline Disintegrating Oral Tablet
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
Study: NCT04410562
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
Study: NCT01343186
Drug: Peginterferon alfa
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: s,c, 45mcg of Ypeginterferon alfa-2a
Study: NCT01343186
Drug: Peginterferon alfa 2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Study: NCT01343186
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Study: NCT01343186
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Study: NCT02912494
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02994082
Drug: Nicotine replacement therapy - transdermal nicotine patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study: NCT02994082
Drug: Nicotine replacement therapy - nicotine lozenge
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study: NCT02994082
Drug: Nicotine replacement therapy - nicotine gum
Normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study: NCT02994082
Drug: Bupropion sustained release
Normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study: NCT02994082
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study: NCT02994082
Drug: Combination nicotine replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
Study: NCT02994082
Drug: Combination nicotine replacement therapy + bupropion
Normalized name: nicotinic acid, combinations
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
Study: NCT01109121
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 400 mg, QD
Study: NCT01157572
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
Study: NCT00104416
Drug: lamotrigine (LAMICTAL) extended-release
Normalized name: lamotrigine Extended Release Oral Tablet
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary experimental dosage form
Study: NCT01450696
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Study: NCT01450696
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Study: NCT00515606
Drug: helium:oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03668496
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
Study: NCT00073736
Drug: MB07133 300mg/m2/day
DrugBank: MB07133 (DB17139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day continuous infusion in 28-day cycles
Study: NCT00073736
Drug: MB07133 600 mg/m2/day
DrugBank: MB07133 (DB17139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day continuous infusion in 28-day cycles
Study: NCT00073736
Drug: MB07133 1200 mg/m2/day
DrugBank: MB07133 (DB17139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day continuous infusion in 28-day cycles
Study: NCT00073736
Drug: MB07133 1800 mg/m2/day
DrugBank: MB07133 (DB17139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day continuous infusion in 28-day cycles
Study: NCT00073736
Drug: MB07133 2400 mg/m2/day
DrugBank: MB07133 (DB17139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day continuous infusion in 28-day cycles
Study: NCT00883168
Drug: azelastineHcl
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: azelastine hydrochloride 548 mg
Study: NCT00883168
Drug: fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fluticasone propionate 200 mcg
Study: NCT00883168
Drug: azelastine Hcl/fluticasone propionate
Normalized name: azelastine HCl/fluticasone propionate 137 mcg-50 mcg/spray NASAL AEROSOL, SPRAY WITH PUMP (GRAM)
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
Study: NCT00610857
Drug: Anti-CTLA4 monoclonal antibody and HDI
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months.
Study: NCT04296305
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV after
Study: NCT02460367
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02460367
Drug: Indoximod
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03629223
Drug: Tepotinib TF2
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
Study: NCT03629223
Drug: Tepotinib TF3
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
Study: NCT02853552
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800mcg misoprostol taken sublingually
Study: NCT04475523
Drug: CI-8993
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
Study: NCT00100074
Drug: Lobeline
Normalized name: lobeline
DrugBank: Lobeline (DB05137)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00586716
Drug: intravenous immune globulin
Normalized name: Intravenous immune globulin (human)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
Study: NCT03115827
Drug: Droxidopa
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Study: NCT03115827
Drug: Carbidopa
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbidopa 200mg twice a day
Study: NCT01312493
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
Study: NCT00203866
Drug: G250 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00203866
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02728648
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pain Management
Study: NCT03668470
Drug: Dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dulaglutide 1.5mg : One injection per week during 24 weeks
Study: NCT00964002
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03773536
Drug: Artesunate-amodiaquine given with single low dose primaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
Study: NCT01584791
Drug: clopidogrel napadisilate + aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel napadisilate 75mg + aspirin 100mg
Study: NCT01584791
Drug: clopidogrel bisulfate + aspirin
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel bisulfate 75mg + aspirin 100mg
Study: NCT02771574
Drug: Lyo avexitide
Normalized name: Avexitide
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
Study: NCT02771574
Drug: Liq avexitide
Normalized name: Avexitide
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
Study: NCT01920919
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00323960
Drug: 3 MPDN pulse + PDN + CSA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
Study: NCT00323960
Drug: 3 MPDN pulse + PDN + MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
Study: NCT01780337
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal dose of 20 IU oxytocin